Illumina, Inc. (NASDAQ:ILMN) Q4 2023 Earnings Conference Call November 9, 2023 5:00 PM ETCompany ParticipantsSalli Schwartz - Vice President of Investor RelationsJacob Thaysen - Chief Executive OfficerJoydeep Goswami - Chief Financial Officer, Chief Strategy and Corporate Development OfficerConference Call ParticipantsVijay Kumar - Evercore ISIDan Brennan - TD CowenPuneet Souda - Leerink PartnersDan Arias - StifelMichael Ryskin - Bank of AmericaTejas Savant - Morgan StanleyDan Leonard - UBSSung Ji Nam - Sco ...

Summary of Illumina, Inc. Conference Call Company Overview - **Company**: Illumina, Inc. (NASDAQ:ILMN) - **Event**: Morgan Stanley 21st Annual Global Healthcare Conference - **Date**: September 11, 2023 - **Participants**: Joydeep Goswami (CFO), Salli Schwartz (VP of Investor Relations), Tejas Savant (Morgan Stanley) Key Points Leadership Changes - Jacob Thaysen's appointment as CEO is seen as a fresh start for Illumina, emphasizing a renewed focus on core operations and improved margins [2][3] Market Challenges - Illumina has cut guidance for sequencing due to: - Competitive pressures from BGI in China - Macro economic weaknesses - Increased competition and government preference for local sourcing [3][5] - The company does not foresee a recovery in the Chinese market in the near future, citing ongoing competitive intensity and regulatory restrictions [5][6] Competitive Landscape - Competitive pressure is primarily observed in mid-throughput segments, while high-throughput segments remain less affected due to unique value propositions [6][7] - Illumina continues to extract a premium for its innovative products despite price competition [7][8] Product Performance - The NovaSeq X has achieved approximately 10% penetration among existing customers, with a focus on multi-unit customers for higher adoption rates [13][14] - Technical issues during the rollout of the NovaSeq X have been addressed, with most fixes deployed [15][16] Financial Guidance and Margins - Illumina aims for a 25% operating margin target for core operations, though this is described as "stretchy" given current market conditions [32][33] - The company is focused on cost management and productivity initiatives while maintaining commitment to innovation [33][34] GRAIL Divestiture - The divestiture of GRAIL is anticipated, with timing dependent on ongoing legal proceedings and regulatory decisions [34][35] - The company is prepared for various divestiture options based on the outcomes of these cases [36] Future Strategy - Illumina is exploring tuck-in acquisitions and partnerships to enhance its technology offerings, particularly in multiomics and spatial biology [38][39] - The company is committed to balancing hardware sales with value-added applications to capture more market share and improve customer utility [40][41] Additional Insights - Illumina's pricing strategy focuses on value rather than merely competing on price, aiming to address customer pain points and improve overall utility [28][30] - The company acknowledges the need for ongoing innovation to maintain its market leadership and adapt to changing customer needs [30][41]

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_254892f25802eaac1a5d82eb4b0a9a04.html ...

Illumina, Inc. (NASDAQ:ILMN) Q2 2023 Results Earnings Conference Call August 9, 2023 5:00 PM ET Company Participants Salli Schwartz - Vice President of Investor Relations Charles Dadswell - Interim Chief Executive Officer and General Counsel Joydeep Goswami - Chief Financial Officer, Chief Strategy and Corporate Development Officer Conference Call Participants Puneet Souda - SVB Leerink Dan Brennan - TD Cowen Dan Arias - Stifel Financial Vijay Kumar - Evercore ISI Tejas Savant - Morgan Stanley Sung Ji Nam - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended July 2, 2023 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-35406 Illumina, Inc. (Exact name of registrant as specified in its charter) Delaware 33-0804655 (State or other jurisdiction of incorporation or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended April 2, 2023 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-35406 Illumina, Inc. (Exact name of registrant as specified in its charter) Delaware 33-0804655 (State or other jurisdiction of incorporation o ...

Illumina, Inc. (NASDAQ:ILMN) Q1 2023 Earnings Conference Call April 25, 2023 5:00 PM ET Company Participants Salli Schwartz - Vice President of Investor Relations Francis deSouza - President and Chief Executive Officer Joydeep Goswami - Chief Financial Officer and Chief Strategy and Corporate Development Officer Conference Call Participants Puneet Souda - SVB Securities Dan Brennan - TD Cowen Dan Arias - Stifel Vijay Kumar - Evercore ISI Tejas Savant - Morgan Stanley Julia Qin - J.P. Morgan David Westenberg ...

Illumina, Inc. (NASDAQ:ILMN) Q3 2022 Earnings Conference Call November 3, 2022 5:00 PM ET Company Participants Salli Schwartz - Vice President of Investor Relations Francis deSouza - President & Chief Executive Officer Joydeep Goswami - Chief Strategy & Corporate Development Officer, Interim Chief Financial Officer Conference Call Participants Dan Brennan - Cowen Vijay Kumar - Evercore ISI Dan Arias - Stifel Puneet Souda - SVB Securities Julia Qin - JPMorgan David Westenberg - Piper Sandler Michael Ryskin - ...